ESC Professional Premium Access

Late-Breaking Science - Innovations in drug treatment

Event: ESC Congress 2022
Topic: European Society of Cardiology
Session type: Late-Breaking Science
Date: 26 August 2022
Time: 11:15 - 12:15

Congress Session

Become an ESC Professional member to access this resource

Become a member

Already a member? Sign in

4 presentations in this session

Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Lifetime prediction and Treatment Benefit in HFrEF (LIFE-HF).

Speaker: Doctor S. Koudstaal (Gouda, NL)

Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial

Speaker: Doctor B. Ingraham (Rochester, US)

ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.

Speaker: Professor D. Bhatt (Boston, US)

4 speakers from this session

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)
70 presentations
1 follower

Doctor Stefan Koudstaal

Green Heart Hospital, Gouda (Netherlands (The))
1 presentation
1 follower

Doctor Brenden Ingraham

Mayo Clinic Hospital-Rochester, Rochester (United States of America)
1 presentation
0 follower

Professor Deepak Bhatt

Harvard Medical School, Boston (United States of America)
36 presentations

This platform is supported by

logo Novo Nordisk